IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC Zhou, C., Das Thakur, M., Srivastava, M. K., Zou, W., Xu, H., Ballinger, M., Felip, E., Wakelee, H., Altorki, N. K., Reck, M., Liersch, R., Kryzhanivska, A., Harada, M., Tanaka, H., Hamm, J., McCune, S., McNally, V., Bennett, E., Gitlitz, B., Novello, S. ELSEVIER. 2021: S1374

View details for DOI 10.1016/j.annonc.2021.10.018

View details for Web of Science ID 000731051400003